Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +0.09
Percentage change 0.61	%

Held by: IJR CALF VTI IWM VB VXF PJP IJS SPSM IWN

Index	RUT	P/E	11.49	EPS (ttm)	1.29	Insider Own	3.33%	Shs Outstand	46.48M	Perf Week	12.74%
Market Cap	681.80M	Forward P/E	4.89	EPS next Y	3.02	Insider Trans	-0.33%	Shs Float	44.59M	Perf Month	6.71%
Income	63.59M	PEG	1.06	EPS next Q	0.72	Inst Own	114.03%	Short Float	13.56%	Perf Quarter	-48.41%
Sales	690.31M	P/S	0.99	EPS this Y	7.35%	Inst Trans	2.22%	Short Ratio	4.32	Perf Half Y	-49.54%
Book/sh	19.07	P/B	0.78	EPS next Y	0.15%	ROA	3.99%	Short Interest	6.05M	Perf Year	-57.15%
Cash/sh	8.76	P/C	1.69	EPS next 5Y	10.80%	ROE	7.54%	52W Range	11.16 - 35.95	Perf YTD	-56.19%
Dividend Est.	-	P/FCF	3.69	EPS past 5Y	-	ROI	4.19%	52W High	-58.89%	Beta	0.84
Dividend TTM	-	Quick Ratio	5.70	Sales past 5Y	15.46%	Gross Margin	65.75%	52W Low	32.39%	ATR (14)	0.89
Dividend Ex-Date	-	Current Ratio	6.82	EPS Y/Y TTM	1451.33%	Oper. Margin	14.65%	RSI (14)	48.98	Volatility	6.27% 4.74%
Employees	712	Debt/Eq	0.74	Sales Y/Y TTM	3.15%	Profit Margin	9.21%	Recom	2.78	Target Price	18.00
Option/Short	Yes / Yes	LT Debt/Eq	0.73	EPS Q/Q	-21.44%	Payout	0.00%	Rel Volume	1.03	Prev Close	14.69
Sales Surprise	2.47%	EPS Surprise	27.34%	Sales Q/Q	5.05%	Earnings	Jul 30 AMC	Avg Volume	1.40M	Price	14.78
SMA20	3.98%	SMA50	-11.76%	SMA200	-43.64%	Trades		Volume	1,229,664	Change	0.61%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-24	Downgrade	Truist	Buy → Sell	$30 → $8
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$37 → $14
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral	$42 → $11
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight	$45 → $10
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight	$38 → $25
Mar-07-24	Resumed	JP Morgan	Overweight	$80 → $45
Dec-20-23	Initiated	Raymond James	Outperform	$42
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform	$50
Jan-31-23	Resumed	Wedbush	Outperform	$88 → $60
Oct-21-22	Resumed	Jefferies	Buy	$66
Jan-03-22	Resumed	JP Morgan	Overweight	$75 → $83
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight	$75
Apr-21-21	Resumed	JP Morgan	Neutral	$70
Apr-09-21	Initiated	Berenberg	Buy	$93
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$86
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform	$72 → $75
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$75
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform	$58 → $67
Jul-06-20	Reiterated	Needham	Buy	$52 → $64

Show Previous Ratings

Sep-09-24 04:00PM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-09-24 03:21PM	Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey (GlobeNewswire) -47.67%
Jul-31-24 10:49AM	Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues (Zacks) +5.68%
Jul-30-24 08:58PM	PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
04:14PM	Pacira: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Loading…
04:00PM	Pacira BioSciences Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-29-24 06:00AM	3 Biotech Stocks to Buy on the Dip: July 2024 (InvestorPlace)
Jul-23-24 08:00AM	Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024 (GlobeNewswire)
03:52AM	Nanotechnology in medicine: Who are the leading public companies? (Medical Device Network)
Jul-17-24 09:50AM	Should Value Investors Buy Pacira BioSciences (PCRX) Stock? (Zacks)
Jul-12-24 10:41AM	Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan (Zacks)
Jul-10-24 04:19PM	Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025 (GlobeNewswire) +7.23%
Jun-14-24 02:41AM	Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX) (GuruFocus.com)
Jun-06-24 11:31AM	Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report? (Zacks)
May-30-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
07:00AM	Loading…
May-10-24 07:00AM	Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029 (GlobeNewswire)
May-08-24 04:05PM	Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes (GlobeNewswire) +11.84%
11:35AM	Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues (Zacks)
09:33AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:47AM	Pacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
May-07-24 09:01PM	PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:03PM	Pacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ... (GuruFocus.com)
05:30PM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings (Zacks)
04:13PM	Pacira: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program (GlobeNewswire)
08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
Apr-30-24 08:00AM	Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024 (GlobeNewswire)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-02-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-14-24 08:23AM	Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag (Zacks)
07:00AM	Loading…
Mar-13-24 07:00AM	Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Mar-08-24 11:55PM	Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX) (GuruFocus.com)
Mar-06-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference (GlobeNewswire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Mar-01-24 08:38AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:05AM	Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues (Zacks)
12:28AM	Q4 2023 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-29-24 10:00AM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings (Zacks)
09:15AM	Pacira (PCRX) Matches Q4 Earnings Estimates (Zacks)
08:32AM	Pacira BioSciences Inc (PCRX) Reports Record Revenues and Robust Earnings for Full-Year 2023 (GuruFocus.com)
08:26AM	Pacira: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-22-24 08:00AM	Pacira to Report 2023 Financial Results on Thursday February 29, 2024 (GlobeNewswire)
Feb-15-24 08:36AM	Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy (GlobeNewswire)
Feb-07-24 08:00AM	Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc. (GlobeNewswire) -7.44%
Feb-01-24 10:45AM	G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams (PR Newswire)
Jan-05-24 12:21PM	Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong (Zacks) +5.71%
Jan-04-24 05:00PM	Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues (GlobeNewswire)
Jan-03-24 08:00AM	Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 07:30AM	Pacira Appoints Frank D. Lee as Chief Executive Officer (GlobeNewswire)
Dec-06-23 11:13AM	Hedge Funds are Betting on These 14 Sliding Stocks (Insider Monkey)
Nov-13-23 10:10AM	Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion (Zacks)
Nov-10-23 07:30AM	Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications (GlobeNewswire)
Nov-07-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November (GlobeNewswire)
Nov-04-23 10:28AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 12:34PM	Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated (Zacks)
10:00AM	Pacira BioSciences Inc (PCRX) Reports Q3 2023 Financial Results (GuruFocus.com)
08:23AM	Pacira: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Pacira BioSciences Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-26-23 08:00AM	Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023 (GlobeNewswire)
Oct-12-23 08:00AM	American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc. (GlobeNewswire)
Oct-10-23 08:00AM	Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors (GlobeNewswire)
Oct-02-23 08:00AM	American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care (GlobeNewswire)
Sep-27-23 12:07PM	Unraveling the Future of Pacira BioSciences Inc (PCRX): A Deep Dive into Key Metrics (GuruFocus.com) -6.51%
11:50AM	Unveiling Pacira BioSciences (PCRX)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-26-23 04:30PM	Pacira BioSciences Announces Leadership Succession Plan (GlobeNewswire)
Sep-06-23 08:00AM	Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 10:03AM	Qualcomm downgraded, Wingstop upgraded: Wall Street's top analyst calls (The Fly) +5.56%
Aug-02-23 12:45PM	Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated (Zacks)
08:11AM	Pacira: Q2 Earnings Snapshot (AP Finance)
08:00AM	Pacira BioSciences Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-26-23 08:00AM	Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023 (GlobeNewswire)
Jun-21-23 08:00PM	PCRX: Raising target price to $42.00 (Argus Research)
Jun-02-23 11:31AM	Why Is Pacira (PCRX) Down 11.8% Since Last Earnings Report? (Zacks)
May-31-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-09-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-03-23 11:42PM	Q1 2023 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -7.17%
05:25PM	Why Pacira BioSciences Shares Are Trading Lower Today (Benzinga)
03:11PM	Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat (Zacks)
08:11AM	Pacira: Q1 Earnings Snapshot (AP Finance)
08:00AM	Pacira BioSciences Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 08:00PM	PCRX: Lowering target price to $35.00 (Argus Research)
08:00AM	Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023 (GlobeNewswire)
Apr-20-23 09:20AM	A Look At The Fair Value Of Pacira BioSciences, Inc. (NASDAQ:PCRX) (Simply Wall St.)
08:00AM	Pacira BioSciences Partners with The Invited Celebrity Classic a PGA TOUR Champions Event to Make iovera° The Official Non-Opioid Pain Management Partner (GlobeNewswire)
Apr-19-23 08:00AM	Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer (GlobeNewswire)
Apr-12-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-03-23 08:00AM	Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources (GlobeNewswire)
Mar-30-23 11:30AM	Why Is Pacira (PCRX) Down 6% Since Last Earnings Report? (Zacks)
Mar-29-23 08:00AM	Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures (GlobeNewswire)
Mar-27-23 08:00AM	Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit (GlobeNewswire)
Mar-24-23 08:50AM	Pacira BioSciences (NASDAQ:PCRX) shareholders have lost 49% over 1 year, earnings decline likely the culprit (Simply Wall St.)
Mar-22-23 08:00AM	Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors (GlobeNewswire)
Mar-09-23 09:17AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference (GlobeNewswire)
Feb-28-23 11:39PM	Q4 2022 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:00AM	Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results (GlobeNewswire)
Feb-23-23 08:00AM	LPGA, Pacira BioSciences Partner to Raise Awareness of Non-Opioid Pain Management Solutions (GlobeNewswire)
Feb-21-23 08:00AM	Pacira to Report 2022 Financial Results on Tuesday February 28, 2023 (GlobeNewswire)

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GAUGLER DARYL	Chief Operating Officer	Sep 13 '24	Sale	12.86	500	6,430	115,700	Sep 13 08:29 PM
GAUGLER DARYL	Officer	Sep 13 '24	Proposed Sale	12.86	500	6,430		Sep 13 10:17 AM
BIGAL MARCELO	Director	Aug 16 '24	Buy	13.25	1,512	20,034	10,142	Aug 19 08:25 AM
Brege Laura	Director	Aug 16 '24	Buy	12.81	1,000	12,810	17,552	Aug 19 08:25 AM
YANG MICHAEL J.	Director	Aug 14 '24	Buy	12.90	2,000	25,800	7,230	Aug 14 04:35 PM
Lee Frank D.	Chief Executive Officer	Aug 12 '24	Buy	12.10	8,264	99,994	107,784	Aug 13 04:55 PM
Froimson Mark	Director	Aug 12 '24	Buy	11.58	1,400	16,212	14,473	Aug 12 08:33 PM
BIGAL MARCELO	Director	Aug 12 '24	Buy	12.01	3,400	40,834	8,630	Aug 12 08:33 PM
SLONIN JONATHAN	Chief Medical Officer	Aug 02 '24	Sale	20.05	945	18,947	94,307	Aug 02 06:00 PM
SLONIN JONATHAN	Officer	Aug 02 '24	Proposed Sale	20.05	945	18,947		Aug 02 10:09 AM
SLONIN JONATHAN	Chief Medical Officer	Jul 02 '24	Sale	28.25	2,836	80,117	95,557	Jul 03 06:52 PM
RIKER LAUREN	Senior Vice President, Finance	Jun 12 '24	Sale	28.72	3,970	114,018	38,075	Jun 13 06:15 PM
SLONIN JONATHAN	Chief Medical Officer	Jun 11 '24	Sale	28.57	5,012	143,193	44,569	Jun 13 06:15 PM
GAUGLER DARYL	Chief Operating Officer	Jun 13 '24	Sale	28.38	1,000	28,380	116,040	Jun 13 06:13 PM
HASTINGS PAUL J	Director	Jun 13 '24	Sale	28.38	880	24,974	12,724	Jun 13 06:13 PM
WILLIAMS KRISTEN	Chief Administrative Officer	Jun 13 '24	Sale	28.38	7,452	211,488	102,912	Jun 13 06:12 PM
PACE GARY W	Director	Mar 08 '24	Sale	30.60	90,000	2,754,000	22,127	Mar 08 05:33 PM
PACE GARY W	Director	Mar 07 '24	Sale	30.81	28,257	870,598	112,127	Mar 08 05:33 PM
PACE GARY W	Director	Mar 06 '24	Sale	29.67	1,066	31,628	140,384	Mar 08 05:33 PM

Open in Screener

ACAD

Acadia Pharmaceuticals Inc

Sep 20 • 03:00PM ET

16.52

Dollar change +0.10
Percentage change 0.62	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

ACAD Acadia Pharmaceuticals Inc daily Stock Chart

Held by: VTI XBI IWM VB FBT VXF VBK IBB IWO SCHA

Index	RUT	P/E	92.56	EPS (ttm)	0.18	Insider Own	0.76%	Shs Outstand	164.65M	Perf Week	1.24%
Market Cap	2.74B	Forward P/E	19.09	EPS next Y	0.87	Insider Trans	-9.59%	Shs Float	164.62M	Perf Month	3.71%
Income	30.57M	PEG	-	EPS next Q	0.13	Inst Own	97.47%	Short Float	6.24%	Perf Quarter	7.98%
Sales	890.53M	P/S	3.08	EPS this Y	250.04%	Inst Trans	0.91%	Short Ratio	6.06	Perf Half Y	-10.26%
Book/sh	3.12	P/B	5.30	EPS next Y	55.89%	ROA	3.93%	Short Interest	10.27M	Perf Year	-30.55%
Cash/sh	3.02	P/C	5.47	EPS next 5Y	-	ROE	6.70%	52W Range	14.55 - 32.59	Perf YTD	-47.23%
Dividend Est.	-	P/FCF	34.05	EPS past 5Y	28.03%	ROI	5.42%	52W High	-49.30%	Beta	0.39
Dividend TTM	-	Quick Ratio	1.95	Sales past 5Y	27.73%	Gross Margin	91.72%	52W Low	13.55%	ATR (14)	0.56
Dividend Ex-Date	-	Current Ratio	2.16	EPS Y/Y TTM	126.79%	Oper. Margin	2.56%	RSI (14)	54.00	Volatility	2.86% 3.30%
Employees	598	Debt/Eq	0.11	Sales Y/Y TTM	61.65%	Profit Margin	3.43%	Recom	1.79	Target Price	25.11
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	2854.41%	Payout	-	Rel Volume	0.40	Prev Close	16.42
Sales Surprise	2.55%	EPS Surprise	12.55%	Sales Q/Q	46.44%	Earnings	Aug 06 AMC	Avg Volume	1.69M	Price	16.52
SMA20	2.57%	SMA50	-2.00%	SMA200	-17.32%	Trades		Volume	577,538	Change	0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28 → $20
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$31
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35
Oct-17-23	Initiated	UBS	Buy	$33
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight	$29 → $32
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$22
Nov-04-22	Downgrade	Goldman	Neutral → Sell	$15 → $12
Nov-01-22	Initiated	Loop Capital	Hold	$17
Aug-08-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15
Aug-05-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15
Jun-21-22	Downgrade	Jefferies	Buy → Underperform	$25 → $10
Jun-16-22	Upgrade	Jefferies	Hold → Buy	$25

Show Previous Ratings

Aug-29-24 08:30AM	Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options (Zacks)
Aug-28-24 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-14-24 08:04AM	Ryan Reynolds Announces More to Parkinsons Campaign (Business Wire)
Aug-07-24 04:30PM	Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire) -19.52%
04:14PM	Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' (Investor's Business Daily)
08:16AM	Loading…
08:16AM	Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues (Zacks)
Aug-06-24 05:45PM	Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:42PM	Acadia: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview (Business Wire)
Jul-30-24 10:01AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-24-24 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024 (Business Wire)
Jul-18-24 09:04AM	Clinical Data from Open-Label Extension LILAC-1 and LILAC-2 Studies Evaluating Long-Term Safety and Efficacy of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Med (Business Wire)
Jul-16-24 10:28AM	Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe (Zacks)
Jun-21-24 12:24PM	Why Is ACADIA Pharmaceuticals Inc (ACAD) One of the Best Debt Free Halal Stocks According to Hedge Funds? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
09:04AM	Loading…
Jun-18-24 09:04AM	Acadia Pharmaceuticals Presents DAYBUE (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting (Business Wire)
Jun-07-24 11:30AM	Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue? (Zacks)
May-29-24 10:01AM	3 Sorry Pharma Stocks to Sell in May While You Still Can (InvestorPlace)
May-17-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-15-24 09:05AM	Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome (Business Wire)
May-10-24 01:15PM	ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches (GuruFocus.com)
11:20AM	UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating (MT Newswires)
10:01AM	Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating (MT Newswires)
May-09-24 04:58PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire) -11.21%
03:29PM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:07AM	Stifel Adjusts Price Target on ACADIA Pharmaceuticals to $21 From $26, Keeps Hold Rating (MT Newswires)
05:59AM	Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss (Zacks)
03:37AM	ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ... (GuruFocus.com)
May-08-24 08:57PM	ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:15PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates (Zacks)
04:15PM	Loading…
04:15PM	Acadia: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview (Business Wire)
May-04-24 02:27AM	Insider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) (GuruFocus.com)
May-01-24 10:01AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-30-24 12:17PM	UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating (MT Newswires)
Apr-29-24 04:16PM	Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship (Business Wire)
Apr-24-24 04:05PM	Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 (Business Wire)
Apr-22-24 09:04AM	Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada (Business Wire)
Apr-20-24 09:15AM	5 Best Healthcare Stocks to Buy Under $20 (Insider Monkey)
Apr-19-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-24 04:05PM	Acadia Pharmaceuticals Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting (Business Wire)
Apr-11-24 02:10PM	3 Pharma Stocks to Sell in April Before They Crash & Burn (InvestorPlace)
Apr-10-24 01:28AM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares (GuruFocus.com)
Apr-02-24 04:05PM	Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development (Business Wire)
Apr-01-24 04:05PM	Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-28-24 11:30AM	Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report? (Zacks)
02:00AM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares (GuruFocus.com)
Mar-20-24 01:31PM	Billionaire Steve Cohen and Insiders are Buying These 5 Stocks (Insider Monkey)
Mar-15-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace)
Mar-13-24 04:05PM	Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day (Business Wire)
Mar-12-24 04:08PM	Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study (Investor's Business Daily) -17.20%
03:05PM	Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short (Investopedia)
11:06AM	Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails (Zacks)
09:30AM	Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today? (InvestorPlace)
07:43AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Mar-11-24 04:46PM	UPDATE 2-Acadia to stop trials of antipsychotic drug after it fails schizophrenia study (Reuters)
04:13PM	Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study (Reuters)
04:05PM	Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia (Business Wire)
Feb-29-24 09:05AM	Acadia Pharmaceuticals to Participate in TD Cowens 44th Annual Health Care Conference on March 6, 2024 (Business Wire)
08:44AM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:05PM	Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile Launch (Investor's Business Daily) -9.92%
09:12AM	Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down (Zacks)
Feb-27-24 05:20PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Zacks)
04:56PM	ACADIA Pharmaceuticals Inc. Reports Strong Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:27PM	Acadia: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview (Business Wire)
Feb-22-24 08:16PM	ACADIA Pharmaceuticals Inc. Investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Feb-21-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-20-24 10:00AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-13-24 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace)
Jan-30-24 08:48PM	Acadia Announces Additions to Executive Team (Business Wire)
05:00PM	20 Countries With The Highest Number of Drug Trafficking in the World (Insider Monkey)
Jan-26-24 05:31PM	Best Drug and Alcohol Rehab Centers in Each of 30 Biggest Cities in the US (Insider Monkey)
Jan-25-24 08:42AM	10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts (Insider Monkey)
Jan-19-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-18-24 04:05PM	Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic (Business Wire)
Jan-12-24 05:02PM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 3,732 Shares (GuruFocus.com)
Dec-21-23 04:05PM	Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 (Business Wire) +6.37%
Dec-18-23 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-13-23 09:24PM	Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID (pimavanserin) (Business Wire) +34.48%
04:14PM	Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug (Investor's Business Daily)
01:41PM	Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID (pimavanserin) Patent Litigation (Business Wire)
Nov-30-23 09:05AM	Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome (Business Wire)
Nov-27-23 09:05AM	Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimers Disease Psychosis (Business Wire)
Nov-21-23 11:03PM	Insider Sell Alert: EVP Brendan Teehan Sells Shares of ACADIA Pharmaceuticals Inc (GuruFocus.com)
05:00PM	Acadia Pharmaceuticals Announces Change in Research and Development Leadership (Business Wire)
Nov-17-23 09:40AM	Are Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year? (Zacks)
Nov-16-23 08:42AM	Implied Volatility Surging for On ACADIA Pharmaceuticals (ACAD) Stock Options (Zacks)
Nov-14-23 04:12PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-08-23 05:24PM	3 Biotech Stocks With the Strongest Clinical Pipelines (InvestorPlace) -5.09%
Nov-04-23 01:10PM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 06:51PM	ACADIA Pharmaceuticals Inc. Reports Record Revenues in Q3 2023 (GuruFocus.com)
04:37PM	Acadia: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview (Business Wire)
Oct-31-23 04:05PM	Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference (Business Wire)
Oct-26-23 10:02AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-23-23 09:05AM	Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program (Business Wire)
Oct-19-23 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023 (Business Wire)

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 19 '24	Sale	15.28	9,733	148,720	43,735	Aug 20 06:46 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Aug 19 '24	Sale	15.28	9,534	145,680	52,177	Aug 20 06:43 PM
DAVIS STEPHEN	CEO	Aug 19 '24	Sale	15.28	31,747	485,094	186,555	Aug 20 06:40 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Jun 10 '24	Sale	14.79	975	14,420	34,564	Jun 11 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 02 '24	Sale	16.94	3,503	59,341	32,053	May 03 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	May 02 '24	Sale	16.94	3,477	58,900	42,133	May 03 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 02 '24	Sale	16.94	1,326	22,462	14,370	May 03 06:00 PM
DAVIS STEPHEN	CEO	May 02 '24	Sale	16.94	11,427	193,573	155,231	May 03 06:00 PM
DAVIS STEPHEN	CEO	Apr 08 '24	Sale	17.87	26,574	474,877	144,267	Apr 09 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Apr 08 '24	Sale	17.87	2,568	45,890	38,796	Apr 09 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 08 '24	Sale	17.87	1,790	31,987	13,100	Apr 09 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 08 '24	Sale	17.87	2,716	48,535	28,742	Apr 09 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Mar 27 '24	Sale	17.90	5,140	92,006	36,340	Mar 27 08:00 PM
DAVIS STEPHEN	CEO	Mar 27 '24	Sale	17.90	17,714	317,081	118,842	Mar 27 07:58 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 27 '24	Sale	17.90	5,434	97,269	26,183	Mar 27 07:57 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Feb 26 '24	Sale	24.67	772	19,045	21,067	Feb 27 06:13 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Feb 26 '24	Sale	24.67	624	15,394	31,432	Feb 27 06:10 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Feb 26 '24	Sale	24.67	474	11,694	11,391	Feb 27 06:07 PM
DAVIS STEPHEN	CEO	Feb 26 '24	Sale	24.67	5,577	137,585	101,890	Feb 27 06:02 PM
DAVIS STEPHEN	CEO	Jan 08 '24	Sale	29.96	3,732	111,811	96,521	Jan 09 06:00 PM
Teehan Brendan	EVP, COO, Head of Commercial	Jan 08 '24	Sale	29.96	731	21,901	30,949	Jan 09 06:00 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Jan 08 '24	Sale	29.96	590	17,676	46,901	Jan 09 06:00 PM
Kihara James	Principal Accounting Officer	Dec 15 '23	Sale	28.30	2,000	56,600	11,025	Dec 15 07:37 PM
Teehan Brendan	EVP, COO, Head of Commercial	Nov 20 '23	Sale	22.64	4,960	112,294	30,393	Nov 21 06:00 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Nov 20 '23	Sale	22.64	5,108	115,645	20,486	Nov 21 06:00 PM
Kihara James	Principal Accounting Officer	Nov 20 '23	Sale	22.64	1,985	44,940	13,025	Nov 21 06:00 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Oct 06 '23	Sale	21.96	16,369	359,463	45,857	Oct 06 10:00 PM
DAVIS STEPHEN	CEO	Oct 06 '23	Sale	21.96	51,563	1,132,323	89,131	Oct 06 09:59 PM

PCRX

Pacira BioSciences Inc

ACAD

Acadia Pharmaceuticals Inc

Upgrade your FINVIZ experience